Newly found peptide curbed appetite in mice and pigs

Peptide hormones are among the most pharmacologically useful molecules in metabolism, and GLP-1 is the obvious example of how one small fragment can become a major therapy. Those active fragments are carved out of larger precursor proteins by enzymes, notably prohormone convertase 1/3. The catch is that the full catalogue of peptides these enzymes generate has never been mapped, so the field has been discovering bioactive fragments more or less by accident. If the cleavage products could be predicted systematically, whole families of unexamined candidate hormones would become available to test.

The authors used computational drug discovery to systematically map more than 2,600 previously uncharacterised human proteolytic peptide fragments predicted to be cleaved by prohormone convertases, then screened for bioactivity. From this pipeline they picked out a 12-mer peptide they named BRINP2-related peptide, or BRP. BRP was then administered pharmacologically to animals, and food intake and anti-obesity effects were assessed in both mice and pigs, alongside checks for nausea or aversion. Mechanistic work looked at central FOS activation as a marker of neuronal activity, and tested whether the effect required leptin, the GLP-1 receptor or the melanocortin 4 receptor.

BRP administration reduced food intake and produced anti-obesity effects in mice and in pigs, and it did so without inducing nausea or aversion, which is notable because gastrointestinal side effects limit tolerability of existing appetite-reducing drugs. Mechanistically, BRP triggered central FOS activation, indicating action in the brain. Critically, its effects did not depend on leptin, on the GLP-1 receptor, or on the melanocortin 4 receptor, marking it out as a non-incretin pathway rather than a variation on current therapies. The broader output was the method itself: a catalogue of more than 2,600 candidate peptide fragments, most of which remain untested.

Almost all recent momentum in appetite pharmacology has run through incretin biology and the GLP-1 receptor. A peptide that reduces intake while bypassing that receptor, and also leptin and melanocortin 4 receptor signalling, suggests the map of appetite-regulating hormones is still incomplete. The prediction-first approach also extends the toolkit: rather than isolating hormones one at a time, the convertase cleavage space can be enumerated. The open questions are large. Whether BRP does anything in humans, at what exposures, with what durability and with what safety profile is entirely untested, and commercial interests are declared.

This is early-stage discovery science, not a treatment, and there is no human evidence in it. What a reader can reasonably take is that appetite regulation is likely broader than the GLP-1 story currently dominating headlines, and that computational screening may accelerate the search for new candidates. The absence of nausea or aversion in animals is an interesting signal, since tolerability is a real constraint on existing drugs, but animal aversion tests are not a guarantee of human tolerability. Anything sold on the basis of this peptide today would be running far ahead of the evidence.